|
| 38030749 | Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. | Br J Cancer | 2024 |
| 36572991 | CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. | Cancer | 2023 |
| 37716223 | Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival. | Gynecol Oncol | 2023 |
| 37856201 | NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. | J Natl Compr Canc Netw | 2023 |
| 36948887 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2023 |
| 36401943 | Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. | Gynecol Oncol | 2023 |
| 34173196 | Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. | J Gen Intern Med | 2022 |
| 35477169 | Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35725031 | Frailty is independently associated with worse outcomes and increased resource utilization following endometrial cancer surgery. | Int J Gynecol Cancer | 2022 |
| 35492879 | A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes. | Cell Rep Med | 2022 |
| 35454861 | CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis. | Cancers (Basel) | 2022 |
| 35816189 | Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. | Clin Cancer Res | 2022 |
| 35387127 | Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma. | Front Oncol | 2022 |
| 36552773 | Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression. | Cells | 2022 |
| 36497028 | Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. | Cells | 2022 |
| 36210504 | Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. | J Natl Cancer Inst | 2022 |
| 36230774 | FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer. | Cancers (Basel) | 2022 |
| 35883104 | DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers. | J Exp Clin Cancer Res | 2022 |
| 35883104 | DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers. | J Exp Clin Cancer Res | 2022 |
| 36222710 | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. | Clin Cancer Res | 2022 |
| 36077735 | Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. | Cancers (Basel) | 2022 |
| 35063280 | Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. | Gynecol Oncol | 2022 |
| 34906490 | Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. | Genet Med | 2022 |
| 34897671 | The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT. | Clin Genet | 2022 |
| 35077220 | Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. | J Clin Oncol | 2022 |
| 34697060 | DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 34782936 | MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. | Virchows Arch | 2022 |
| 32546565 | Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer. | J Med Genet | 2021 |
| 33852846 | Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. | Cell Rep | 2021 |
| 33852846 | Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. | Cell Rep | 2021 |
| 33891474 | Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. | J Clin Oncol | 2021 |
| 34965417 | Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. | Cell Rep | 2021 |
| 34926762 | Vaginal high-grade sarcoma in pregnancy. | Gynecol Oncol Rep | 2021 |
| 34426412 | Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 34391577 | PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine. | Gynecol Oncol | 2021 |
| 34711227 | Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study. | BMC Womens Health | 2021 |
| 33990587 | Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. | Nat Commun | 2021 |
| 34081738 | Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. | PLoS One | 2021 |
| 34162658 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 33229045 | Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. | Gynecol Oncol | 2021 |
| 33406487 | Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 32997807 | Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? | CA Cancer J Clin | 2021 |
| 31469419 | Identification of novel epithelial ovarian cancer loci in women of African ancestry. | Int J Cancer | 2020 |
| 31644510 | Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers? | Menopause | 2020 |
| 31839342 | Predictors of survival trajectories among women with epithelial ovarian cancer. | Gynecol Oncol | 2020 |
| 33106023 | Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. | Am Surg | 2020 |
| 32807084 | Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial. | BMC Med Res Methodol | 2020 |
| 32970483 | 21 Code of Federal Regulations Part 11-Compliant Digital Signature Solution for Cancer Clinical Trials: A Single-Institution Feasibility Study. | JCO Clin Cancer Inform | 2020 |
| 32796289 | Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. | Menopause | 2020 |
| 32766252 | Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary? | Front Cell Dev Biol | 2020 |